After a long history of failed clinical trials, we are currently experiencing an enthusiastic era for the treatment of amyloid-related neurodegenerative diseases. Phase1b data of aducanumab, a fully human antibody against Abeta42, is giving great promises and it is now moving directly into Phase3 in prodromal AD. Ponezumab, an antibody against Abeta40, has recently entered in Phase2 for CAA. Although the differences in terms of naturally history of these diseases and of drug-target engagement, increasing data are demonstrating that CAA and AD share different similarities that can perhaps mutually influence the design, safety, biomarkers profile and final outcomes interpretation of clinical trials
Piazza, F. (2016). Symposium Immunotherapy Trials in CAA and AD: The ARIA paradox in AD and CAA: merely an adverse event or an out of tune proof of immunotherapy effectiveness?. In International CAA Conference September 8-10 2016 Boston MA.
Symposium Immunotherapy Trials in CAA and AD: The ARIA paradox in AD and CAA: merely an adverse event or an out of tune proof of immunotherapy effectiveness?
PIAZZA, FABRIZIO
Primo
2016
Abstract
After a long history of failed clinical trials, we are currently experiencing an enthusiastic era for the treatment of amyloid-related neurodegenerative diseases. Phase1b data of aducanumab, a fully human antibody against Abeta42, is giving great promises and it is now moving directly into Phase3 in prodromal AD. Ponezumab, an antibody against Abeta40, has recently entered in Phase2 for CAA. Although the differences in terms of naturally history of these diseases and of drug-target engagement, increasing data are demonstrating that CAA and AD share different similarities that can perhaps mutually influence the design, safety, biomarkers profile and final outcomes interpretation of clinical trials
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
